1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization

 
• By Brenda Sandburg

Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.

Clouds-Lightning-Storm_1200x675
FDA dealing with political firestorm after COVID-19 convalescent plasma authorization • Source: Shutterstock

The political firestorm engulfing the US Food and Drug Administration continues, with its chief spokesperson, Emily Miller, being sidelined following fierce criticism of the way the agency handled an emergency use authorization for COVID-19 convalescent plasma. The situation shows the consequences of FDA straying from its strictly science-based approach and the turmoil going on within the agency as it deals with pressures inside and outside the Trump Administration.

The sidelining of Miller, first reported by the New York Times, suggests she was being held accountable, at least in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By Sue Sutter

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.

HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?

 
• By Sarah Karlin-Smith

Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.